(CYRX) Cryoport - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2290503075
CYRX: Temperature-Controlled, Shipping, Storage, Logistics, Consulting
Cryoport, Inc. (NASDAQ:CYRX) specializes in temperature-controlled supply chain solutions for the biopharma, pharma, animal health, and human reproductive medicine sectors globally. The company serves clients across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, offering a comprehensive suite of products and services tailored to the precise temperature requirements of biological materials.
The company’s product portfolio includes the Cryoport Express Shippers, designed for reliable temperature control during transport; the Cryoport ELITE series, which features advanced solutions like the -80°C Gene Therapy Shipper and the Cryosphere Shipper for ultra-low temperature applications. It also provides consulting services, including thermal and shipping system qualifications, custom packaging development, and bioservices such as controlled temperature storage, fulfillment, and secondary packaging. Additionally, Cryoport offers specialized solutions like CRYOGENE for pre-clinical biological materials management and CRYOPD for temperature-controlled logistics.
Cryoport further expands its offerings with MVE Biological Solutions’ cryogenic systems, including the Fusion and Vario freezers, which support a range of temperatures from -20°C to -150°C. The company also provides Cryoshuttle for dedicated local transportation, IntegriCell services for apheresis/leukapheresis collection and cryo-process optimization, and Tec4Med solutions. Its services encompass biological specimen cryopreservation, archiving, tracking, and transportation, as well as short-term logistics and engineering consulting.
Founded in 1999 and headquartered in Brentwood, Tennessee, Cryoport has established itself as a key player in the temperature-controlled logistics and storage market. The company’s focus on innovation and precision has enabled it to meet the growing demands of the biopharma and life sciences industries. Web URL: https://www.cryoportinc.com
Additional Sources for CYRX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CYRX Stock Overview
Market Cap in USD | 308m |
Sector | Industrials |
Industry | Integrated Freight & Logistics |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2005-03-15 |
CYRX Stock Ratings
Growth 5y | -68.5% |
Fundamental | -57.2% |
Dividend | 0.0% |
Rel. Strength Industry | -56.4 |
Analysts | 3.73/5 |
Fair Price Momentum | 4.74 USD |
Fair Price DCF | - |
CYRX Dividends
No Dividends PaidCYRX Growth Ratios
Growth Correlation 3m | -79.6% |
Growth Correlation 12m | -76.8% |
Growth Correlation 5y | -80.2% |
CAGR 5y | -14.37% |
CAGR/Max DD 5y | -0.15 |
Sharpe Ratio 12m | -0.95 |
Alpha | -63.63 |
Beta | 0.71 |
Volatility | 176.17% |
Current Volume | 420.3k |
Average Volume 20d | 337.1k |
As of March 14, 2025, the stock is trading at USD 6.24 with a total of 420,338 shares traded.
Over the past week, the price has changed by -6.31%, over one month by -6.94%, over three months by -18.86% and over the past year by -56.55%.
No, based on ValueRay Fundamental Analyses, Cryoport (NASDAQ:CYRX) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -57.21 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CYRX as of March 2025 is 4.74. This means that CYRX is currently overvalued and has a potential downside of -24.04%.
Cryoport has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold CYRX.
- Strong Buy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CYRX Cryoport will be worth about 5.1 in March 2026. The stock is currently trading at 6.24. This means that the stock has a potential downside of -17.95%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 10.7 | 71.8% |
Analysts Target Price | 11.3 | 81.1% |
ValueRay Target Price | 5.1 | -17.9% |